IGMS vs. AVBP, AVTE, PHAT, CDMO, CALT, APLT, ATXS, STOK, GHRS, and OLMA
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include ArriVent BioPharma (AVBP), Aerovate Therapeutics (AVTE), Phathom Pharmaceuticals (PHAT), Avid Bioservices (CDMO), Calliditas Therapeutics AB (publ) (CALT), Applied Therapeutics (APLT), Astria Therapeutics (ATXS), Stoke Therapeutics (STOK), GH Research (GHRS), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical preparations" industry.
ArriVent BioPharma (NASDAQ:AVBP) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
In the previous week, ArriVent BioPharma and ArriVent BioPharma both had 13 articles in the media. IGM Biosciences' average media sentiment score of 1.22 beat ArriVent BioPharma's score of 0.30 indicating that ArriVent BioPharma is being referred to more favorably in the media.
ArriVent BioPharma currently has a consensus price target of $29.25, indicating a potential upside of 55.59%. IGM Biosciences has a consensus price target of $17.89, indicating a potential upside of 93.39%. Given ArriVent BioPharma's higher probable upside, analysts clearly believe IGM Biosciences is more favorable than ArriVent BioPharma.
9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 56.9% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
IGM Biosciences received 56 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 49.22% of users gave IGM Biosciences an outperform vote.
ArriVent BioPharma has higher earnings, but lower revenue than IGM Biosciences.
ArriVent BioPharma has a net margin of 0.00% compared to ArriVent BioPharma's net margin of -11,255.25%. IGM Biosciences' return on equity of 0.00% beat ArriVent BioPharma's return on equity.
Summary
ArriVent BioPharma beats IGM Biosciences on 7 of the 12 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
